All in all, these data suggest that mutant p53-expressing CRC cell lines possess larger cellular sub-populations that display high-ALDH activity, thus suggesting larger CSCs sub-populations that may account for their higher tumorigenic potential and drug resistance. The gene discussed is TP53; the disease is colorectal carcinoma.